Clinical-use-associated decrease in susceptibility of vancomycin-resistant Enterococcus faecium to linezolid: a comparison with quinupristin-dalfopristin

Antimicrob Agents Chemother. 2004 Sep;48(9):3583-5. doi: 10.1128/AAC.48.9.3583-3585.2004.

Abstract

The susceptibility of 135 vancomycin-resistant Enterococcus faecium bacteremic isolates to linezolid and quinupristin-dalfopristin was determined. All were susceptible to linezolid, while 88% were susceptible to quinupristin-dalfopristin prior to the clinical use of the drugs at our hospital. More than 6 months after their clinical use, a decrease in susceptibility was noted for only linezolid at 83%. This was related in part to a single G2576U gene mutation in domain V of the 23S rRNA gene.

Publication types

  • Comparative Study

MeSH terms

  • Acetamides / pharmacology*
  • Anti-Bacterial Agents / pharmacology*
  • Drug Utilization
  • Electrophoresis, Gel, Pulsed-Field
  • Enterococcus faecium / drug effects*
  • Gram-Positive Bacterial Infections / epidemiology*
  • Gram-Positive Bacterial Infections / microbiology*
  • Humans
  • Linezolid
  • Oxazolidinones / pharmacology*
  • Point Mutation / genetics
  • RNA, Bacterial / genetics
  • RNA, Ribosomal, 23S / genetics
  • Vancomycin Resistance*
  • Virginiamycin / analogs & derivatives*
  • Virginiamycin / pharmacology*

Substances

  • Acetamides
  • Anti-Bacterial Agents
  • Oxazolidinones
  • RNA, Bacterial
  • RNA, Ribosomal, 23S
  • Virginiamycin
  • quinupristin
  • Linezolid